Multivariable Analyses of OS-Related Factors in Unresectable Hepatocellular Carcinoma

A 9.5 KB Excel file containing retrospective real-world data comparing second-line therapies for unresectable hepatocellular carcinoma. The dataset, authored by Chinatsu Nishioka and last updated in May 2026, includes results from a non-randomized comparative study of 81 patients treated with either durvalumab plus tremelimumab or lenvatinib after first-line atezolizumab plus bevacizumab.

Use Cases

• Compare progression-free and overall survival outcomes based on second-line therapy regimen.
• Analyze adverse event frequency and severity between immunotherapy and targeted therapy.
• Model predictors of overall survival based on neutrophil-to-lymphocyte ratio and treatment type.
• Assess changes in liver function using Albumin-Bilirubin (ALBI) score data over time.

Strengths

• Includes specific patient counts for two treatment groups (n=14 and n=67).
• Reports concrete statistical outcomes, such as median PFS of 1.7 vs. 4.2 months and median OS of 5.3 vs. 14.0 months.
• Contains multivariable analysis results identifying independent predictors for PFS and OS.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a retrospective, non-randomized study, which may introduce selection bias.

Provenance

Source

figshare

Collection Method

Retrospective analysis of real-world data from a prospectively registered observational cohort.

Time Range

null

Freshness

Last updated 2026-05 07 18:00:17; freshness should be verified.

Geography

null